Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as lacutamab
IPH4102 · 4 trials · 6 indications
time from randomization until one of the following events occurs, whichever comes first: 1. Disease progression (PD) 2. Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT)) 3. Relapse after achievement of CR 4. Death due to any cause. PD and relapse will be evaluated according to Lugano 2014 criteria (CT-based).
Using the Olsen (2011, JCO) criteria (All cohorts)
Frequency and intensity of adverse events and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| Lacutamab | EXPERIMENTAL | Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase |
| Standard of care | ACTIVE_COMPARATOR | GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase |
| Cohort 1: Relapsed/refractory Sezary Syndrome | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed) | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressing | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| PTCL that express KIR3DL2 | EXPERIMENTAL | lacutamab will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| IPH4102 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Lacutamab | DRUG | 750 mg/IV |
| Gemcitabine | DRUG | 1000 mg/m² |
| Oxaliplatine | DRUG | 100 mg/m² |
| IPH4102 | BIOLOGICAL | Patients will receive a flat dose of 750mg |
Inclusion Criteria: * 1\. KIR3DL2-positive with at least 1% of tumour cells positivity, before randomization, based on central evaluation by immunohistochemistry (IHC) 2. Patients with histologically documented PTCL: * Biopsy-proven treated PTCL defined by the WHO 2016 criteria (the biopsy at re...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib |
IPH4102 is an investigational monoclonal antibody being studied for the treatment of T-cell lymphomas, including cutaneous T-cell lymphoma and mycosis fungoides/Sezary syndrome. It is being developed by Innate Pharma S.A. and is currently in clinical development for these indications.
IPH4102 is a monoclonal antibody designed to target a specific protein on malignant T-cells. The drug is being studied in patients with relapsed or refractory cutaneous T-cell lymphomas, as well as in combination with chemotherapy for advanced T-cell lymphoma.
IPH4102 is being developed by Innate Pharma S.A., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of IPH4102 in patients with T-cell lymphomas.
IPH4102 has completed Phase 1 and Phase 2 clinical trials. The Phase 1 trial evaluated the drug in patients with relapsed or refractory cutaneous T-cell lymphomas, and the Phase 2 trial studied it alone or in combination with chemotherapy in advanced T-cell lymphoma.
IPH4102 has been studied in two clinical trials. NCT02593045 was a Phase 1 trial in patients with relapsed or refractory cutaneous T-cell lymphomas. NCT03902184 was a Phase 2 trial evaluating IPH4102 alone or with chemotherapy in advanced T-cell lymphoma, including mycosis fungoides/Sezary syndrome.
Yes, IPH4102 is also known as lacutamab. In clinical trials, the drug has been referred to as IPH4102/lacutamab, and it is being studied for the treatment of T-cell lymphomas.